Related references
Note: Only part of the references are listed.The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor
Mohammad Eskandari et al.
LEUKEMIA & LYMPHOMA (2021)
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
Andrew H. Wei et al.
BLOOD (2021)
The long and the short of it: the MDM4 tail so far
Sue Haupt et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Luis A. Carvajal et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival
Rita Assi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53
Bridget K. Marcellino et al.
BLOOD ADVANCES (2018)
p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status
A. Quintas-Cardama et al.
LEUKEMIA (2017)
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Julia Abramowitz et al.
BMC MEDICAL GENOMICS (2017)
High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Xin Han et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
When stem cells grow old: phenotypes and mechanisms of stem cell aging
Michael B. Schultz et al.
DEVELOPMENT (2016)
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
Bernhard Reis et al.
HAEMATOLOGICA (2016)
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Jonathan D. Oliner et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
Bernhard Reis et al.
HAEMATOLOGICA (2016)
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
H-A Hou et al.
BLOOD CANCER JOURNAL (2015)
The regulation of MDM2 oncogene and its impact on human cancers
Yuhan Zhao et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2014)
miR-661 downregulates both Mdm2 and Mdm4 to activate p53
Y. Hoffman et al.
CELL DEATH AND DIFFERENTIATION (2014)
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Catharina Mueller-Thomas et al.
HAEMATOLOGICA (2014)
MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
Li Li et al.
PLOS ONE (2014)
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity
Vinod Pant et al.
GENES & DEVELOPMENT (2013)
The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression
Altaf A. Dar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Christine Vogel et al.
NATURE REVIEWS GENETICS (2012)
JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
M. Nakatake et al.
ONCOGENE (2012)
The p53 Tumor Suppressor protein Regulates Hematopoietic Stem Cell Fate
Takashi Asai et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Analysis of the p53 and MDM-2 gene in acute myeloid leukemia
Barbara Seliger et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
p53 Regulates Hematopoietic Stem Cell Quiescence
Yan Liu et al.
CELL STEM CELL (2009)
The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop
Xiongbin Lu et al.
CANCER CELL (2007)
Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival
Vassiliki Zolota et al.
PATHOLOGY RESEARCH AND PRACTICE (2007)
Regulation of HDM2 activity by the ribosomal protein L11
MAE Lohrum et al.
CANCER CELL (2003)
Direct interactions between HIF-1α and Mdm2 modulate p53 function
DL Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
BCR/ABL activates mdm2 rnRNA translation via the La antigen
R Trotta et al.
CANCER CELL (2003)
hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase
H Vaziri et al.
CELL (2001)
Share Paper
